Compare DexCom, Inc. (DXCM) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Micron Technology, Inc. — how do they compare? DexCom, Inc. trades at $77.77 (market cap $28.06B), while Micron Technology, Inc. trades at $864.35 (market cap $1.02T). The key difference: Micron Technology, Inc. is far larger — about 36.4× DexCom, Inc.'s market cap, and Micron Technology, Inc. pays a 0.06% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MU | |
|---|---|---|
Market Cap | $28.06B | $1.02T |
Sector | Health | Technology |
52-Week High | $89.53 | $1.21K |
52-Week Low | $54.84 | $104.88 |
Enterprise Value | $27.03B | $1.00T |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
Micron Technology (MU) trades at $983.12, up 4.92% in the last 24 hours, with a bullish technical signal and strong fundamental momentum. The company has consistently beaten earnings estimates, with Q1 2026 EPS of $25.11 surpassing the $20.98 forecast. Revenue growth is robust, rising to $37.38 billion in 2025, while profitability metrics like a 55.91% net income margin and 32.62% ROE highlight operational efficiency. Recent news reflects mixed sentiment amid AI-driven demand and competitive pressures from Chinese memory makers.
The outlook for MU is positive, driven by AI infrastructure demand and earnings strength, but risks include fierce competition and market volatility. Analysts are overwhelmingly bullish, with an 81.43% buy rating and a consensus price target of $1,550, suggesting significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
